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Abstract 
Weight-loss medications are currently recommended for use 
only as an adjunct to diet, exercise, and behavior modifica­
tion. Little, however, is known about the benefits of com­
bining behavioral and pharmacological therapies or about 
the mechanisms that would make these combined ap­
proaches more effective than either used alone. This article 
reviews the effects of adding pharmacotherapy (i.e., princi­
pally sibutramine and orlistat) to a modest program of 
lifestyle modification. Studies revealed that the addition of 
medication typically improved short- and long-term weight 
loss compared with lifestyle modification alone. The best 
results, however, were obtained when medications were 
combined with an intensive, group program of lifestyle 
modification. The two approaches may have additive 
effects; behavioral treatment seems to help obese individu­
als control the external (i.e., food-related) environment, 
whereas pharmacotherapy may control the internal environ­
ment by reducing hunger, cravings, or nutrient absorption. 
The article examines possible methods of sequencing be­
havioral and pharmacological therapies and offers sugges­
tions for future research. 
Key words: weight-loss medications, sibutramine, 
orlistat, behavior therapy, obesity 
Introduction 
The Food and Drug Administration (FDA), as well as an 
expert panel convened by the National Heart Lung and 
Blood Institute, has recommended that weight-loss medica­
tions be used only as an adjunct to a comprehensive pro­
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gram of lifestyle modification that includes diet, physical 
activity, and behavior therapy (1). A common hypothesis is 
that medication should help facilitate adherence to lifestyle 
modification. By reducing appetite or nutrient absorption, 
medications may make it easier for patients to adhere to a 
low-calorie diet. Surprisingly little, however, is known 
about the specific benefits of combining these therapies, or 
how and when they should be combined. This paper reviews 
evidence from randomized control trials that compare the 
effects of lifestyle modification, pharmacotherapy, and their 
combination. The potential mechanisms of action of com­
bination therapy are explored, and ways to maximize the 
benefits of this approach are discussed. 
Lifestyle Modification 
Lifestyle modification generally consists of a combina­
tion of dietary modification, exercise, and behavior therapy. 
Women who wish to lose weight are usually encouraged to 
eat 1200 to 1500 kcal/d and men are encouraged to eat 1500 
to 1800 kcal/d. Instruction is provided in consuming a 
well-balanced, low-fat diet, as suggested by the Food Guide 
Pyramid (2). In addition, patients may be instructed to select 
foods high in fiber to enhance satiety and nutrition. They are 
also encouraged to gradually increase their physical activity 
to 30 min/d, most days of the week (3). Adherence to diet 
and exercise recommendations is promoted through the use 
of behavioral techniques (4), including recording caloric 
intake and physical activity and limiting the places and 
activities associated with eating and inactivity (i.e., stimulus 
control). Instruction is also provided in cognitive restruc­
turing to prevent relapse. Adherence to these weight-control 
behaviors may be facilitated by the use of reinforcement 
contingencies (e.g., monetary or social support) (5). 
Weight Loss 
Comprehensive behavioral programs, providing weekly 
group treatment of 20 to 26 weeks, produce mean losses of 
8 to 10 kg (�9% of initial body weight) and are associated 
with attrition of �15% to 20%. By contrast, less intensive 
interventions that provide patients with treatment manuals 
and minimal or no therapist contact produce weight losses 
of only 1 to 5 kg over 6 months (6 – 8). 
The well-documented problem with lifestyle modifica­
tion is weight regain after treatment termination. On aver­
age, in the year after treatment, patients regain �30% to 
35% of their weight loss. Approximately 3 to 5 years after 
therapy, 50% or more of participants have returned to their 
baseline weight (9,10). These results are not entirely dis­
couraging considering that most obese people, left untreated 
for 3 to 5 years, would probably gain 0.5 to 1 kg per 
year (11). 
Mechanisms of Action 
Reducing energy intake is the key to short-term weight 
loss; the greater the energy deficit, the greater the loss 
(12,13). Attending treatment sessions and keeping food 
records are consistently related to weight loss (1,5–6), prob­
ably because they facilitate adherence to energy restriction. 
Whereas increased physical activity may contribute mod­
estly to short-term weight loss (14), the role of other 
components of lifestyle modification, including stimulus 
control, problem-solving, cognitive-restructuring, and rein­
forcement contingencies, is unclear. During treatment, cog­
nitive restraint (i.e., cognitive control of eating) and self-
efficacy increase; however, these variables are only 
modestly correlated with weight loss (15,16). 
The maintenance of weight loss is facilitated by patients 
engaging in high levels of physical activity (17–22). Fre­
quent patient-provider contact also prevents weight regain 
(23–26). Behavioral-maintenance therapy, however, seems 
only to delay rather than to prevent weight regain. Atten­
dance of maintenance sessions declines over time, and once 
treatment is terminated, patients regain weight (23). As 
others have suggested (27), it may be asking too much for 
overweight individuals to exert continuous control in the 
face of unremitting biological factors and an environment 
that supplies an abundance of ready-made high-calorie, 
high-fat foods, as well as a multitude of energy-saving 
devices. Interventions are needed that make the day-to-day 
work of weight control easier and more sustainable. Phar­
macotherapy may be helpful in this regard. 
Pharmacotherapy 
Historically, anorectic agents have induced weight loss 
by influencing central nervous system (CNS) receptors as­
sociated with eating and appetite regulation. Noradrenergic 
(e.g., amphetamines) and serotonergic (e.g., fenfluramines) 
agents, for example, were associated with reports of de­
creased hunger and increased satiety, respectively (28). 
Studies also reported macronutrient-specific effects of CNS 
agents (29–31), although the data were contradictory (32–34). 
The history of weight-loss agents has been marked by 
several adverse experiences. In 1997, for example, fenflu­
ramine and dexfenfluramine were withdrawn from the mar­
ket because of their association with valvular heart disease 
(35). Two medications, sibutramine and orlistat, are cur­
rently approved by the FDA for long-term use in obesity 
management. Sibutramine is a CNS agent that inhibits the 
reuptake of norepinephrine and serotonin. By contrast, orl­
istat is a gastric and pancreatic lipase inhibitor that works by 
blocking the absorption of about one-third of the fat con­
tained in a meal; the undigested fat is excreted in stool (36) 
The medications seem to be generally safe and effective 
when used with appropriate persons under medical super­
vision. The clinical use of these medications has been de­
scribed by several investigators (28,37,38). 
Sibutramine 
Weight Loss. Sibutramine, in conjunction with dietary 
therapy, induces weight losses of 4% to 12% of initial body 
weight, which are 3 to 9 percentage points greater than those 
produced by placebo. Losses have been sustained for up to 
2 years with continuous therapy (39,40). Sibutramine has 
also been found to induce weight loss independent of sub­
jects’ efforts to diet and lose weight (41). 
Mechanisms of Action. Sibutramine has been shown to 
reduce energy intake, particularly at lunchtime (42). This 
may be because peak plasma concentration occurred at this 
time, after early morning dosing (41,42). Preliminary re­
search did not find that the medication altered macronutrient 
selection (41,42); however, further studies are needed. Re­
search on the appetite-altering effects of sibutramine has 
yielded mixed findings; 6-month studies showed reductions 
in hunger and increases in fullness (43,44), but shorter-term 
studies found no such effect (45–48). Studies also were 
divided concerning whether the medication has a thermo­
genic effect (47,48); it seems to be very weak, if present. 
Orlistat 
Weight Loss. Orlistat, in conjunction with a reduced-
calorie diet, produces weight losses of 5% to 13% of initial 
body weight. These losses are 2 to 6 percentage points 
greater than those associated with placebo. Weight losses 
are generally well-maintained for up to 2 years, although 
modest weight regain was observed in patients while they 
remained on medication (49,50). 
Mechanisms of Action. Unlike sibutramine, orlistat does 
not affect the CNS and is unlikely to have a direct effect on 
appetite (51). It induces weight loss principally by blocking 
the absorption of about one-third of the fat consumed in a 
meal. However, orlistat also could affect food preference 
through aversive conditioning. Specifically, individuals 
may learn to eat less fat to avoid aversive gastrointestinal 
side-effects that include increased defecation, soft stools, 
fatty/oily evacuation, and oily spotting (50,52,53). In anec­
dotal reports, patients noted that orlistat acted as a “watch­
dog” for dietary compliance (54). Consistent with this hy­
pothesis, one report (55) found that fat intake was generally 
higher in the placebo group than in orlistat-treated partici­
pants, but differences between groups were not statistically 
significant. Another study found similar fat intake in placebo-
and orlistat-treated groups (52). Thus, further research is 
needed to determine orlistat’s effects on food preferences. 
Why Is Medication Recommended Only as
 
an Adjunct to Diet, Exercise, and
 
Behavior Therapy?
 
There are several reasons for recommending that phar­
macotherapy be added to a program of lifestyle modifica­
tion. First, growing evidence shows that a program of mod­
est physical activity can reduce the risk of cardiovascular 
disease, independent of weight status (56,57). Similarly, 
behavioral treatment encourages patients to eat a low-fat, 
low-cholesterol diet, which, by itself, may reduce the risk of 
coronary artery disease (58). These important benefits would 
be lost if weight loss were induced by medication alone. 
Second, without lifestyle modification, pharmacotherapy 
alone might result in suboptimal short- and long-term 
weight losses. Larger weight losses are desirable because 
they are generally associated with greater improvements in 
weight-related health complications (59). They are also 
eagerly desired by obese individuals (60). 
Third, adding pharmacotherapy to lifestyle modification 
fits well with a stepped-care approach in which the least 
aggressive intervention is tried first and, if unsuccessful, is 
augmented by more aggressive interventions. In this model, 
lifestyle modification is the cornerstone of weight manage­
ment, in part, because it is less expensive and has fewer 
side-effects than pharmacotherapy. The next section re­
views research on the effects of adding pharmacotherapy to 
lifestyle modification. 
Does the Addition of Pharmacotherapy
 
Improve the Results of Lifestyle
 
Modification?
 
Most studies of pharmacotherapy compare the effects of 
placebo plus lifestyle modification with medication plus the 
same program of lifestyle modification. These placebo-drug 
studies appropriately test the efficacy of the medication. The 
use, however, of placebos in these trials limits their assess­
ment of lifestyle modification as delivered in clinical prac­
tice. A placebo could diminish the effectiveness of the 
lifestyle-modification program by reducing participants’ in­
volvement in behavioral treatment (61). Nonetheless, the 
placebo-controlled trials reviewed below do provide an as­
sessment of whether adding medication generally improves 
on the results of diet and exercise modification. 
Tables 1 and 2 summarize the results of double-blind 
placebo controlled trials of 6 months or more that used 
sibutramine or orlistat. Participants were overweight or 
obese (i.e., body mass index � 25 kg/m2) adults and were 
predominantly women. Most trials included relatively weak 
programs of lifestyle modification, in part, to better reveal 
the effects of the medications (28). Diet and exercise mod­
ification was typically initiated during a 2- to 4-week single-
blind run-in period, after which subjects were randomized 
into the double-blind phase of the study. The diets generally 
contained 30% fat and were designed to produce a mild 
hypocaloric deficit of 500 to 600 kcal/d. Unless otherwise 
noted, data in the tables reflect weight change beginning 
after the run-in period. Data from subjects who completed 
the trials are reported, unless otherwise noted in the text. 
Induction of Weight Loss 
As indicated in Table 1, sibutramine produced mean 
weight losses that were 3 to 9 kg greater than placebo when 
both interventions were combined with a low-intensity pro­
gram of lifestyle modification. These findings demonstrate 
sibutramine’s efficacy and suggest that the medication can 
improve a modest program of lifestyle modification admin­
istered with a placebo. 
Studies of orlistat plus lifestyle modification produced 
weight losses that were 2 to 6 kg greater than those resulting 
from placebo plus lifestyle change (Table 2). Thus, similar 
to sibutramine, orlistat seems to improve results produced 
by minimal lifestyle modification therapy (with placebo). 
Whether these medications would have the same weight-
loss enhancing effect when combined with a more compre­
hensive lifestyle-intervention program is unknown. Com­
prehensive lifestyle-modification programs provide weekly 
group treatment and specific instruction in diet, exercise, 
and behavioral strategies. By contrast, the low-intensity 
interventions used in most of the studies of sibutramine and 
orlistat provided little (e.g., monthly) or no contact with a 
weight-loss practitioner and only general recommendations 
for modifying eating and exercise habits. Three studies of 
fenfluramine (62–64), as well as one of the fenfluramine­
phentermine combination (65) (summarized in Table 3), 
found that medication, combined with a comprehensive 
program of lifestyle modification, produced significantly 
greater weight loss than the same behavioral program used 
alone or combined with placebo. However, the potential 
benefits of adding medication to a comprehensive lifestyle-
modification program cannot be fully determined until such 
studies are conducted with medications approved for long-
term use. In addition, comparison conditions are required, 
including lifestyle modification without a placebo pill (66). 
Weight-Loss Maintenance 
Pharmacotherapy’s greatest benefit may be in facilitating 
the long-term maintenance of weight loss. Placebo-con­
trolled trials of this issue generally provided the same fre­
quency of follow-up visits as used in behavioral treatment 
(i.e., monthly or quarterly follow-up visits). In this way, the 
Table 1. Randomized double-blind controlled trials of sibutramine and lifestyle modification for obesity 
Randomized/ 6-Month 1-Year 2-Year 
completed Dose weight loss weight loss weight loss Number of 
Reference (n) (mg/QD) (kg) (kg) (kg) counseling visits 
Apfelbaum et al. (67) 81/54 SIB 10 �12.7a* �12.7 (12%)a* 3 in 6 months; total, 5 
78/45 PL � 9.0b* �7.6 (7%)b — over 1 year; dietitian 
provided advice 
Bray et al. (76) 173/147	 SIB 15 7.3 (7.5%)b 1 in 6 months; dietitian 
SIB 20 8.3 (8.8%)b — — provided advice 
PL 0.5 (0.2%)a 
Bray et al. (77)	 152/98 SIB 15 7.0 (7.4%)b 1 in 6 months; dietitian 
146/96 SIB 20 8.2 (8.8%)b — — provided advice 
148/59 PL 1.3 (1.2%)a 
Cuellar et al. (43) 35/22 SIB 15 10.4 (11.8%)a† 7 in 6 months; physician 
34/9 PL 1.3 (1.4%)b† — — provided minimal 
dietary counseling 
Dujovne et al. (94) 162/114 SIB 20 4.9 (4.9%)a† 1 in 6 months 
160/105 PL 0.6 (0.6%)b† (additional sessions, 
— — 
as needed); individual 
dietary counseling 
Fanghanel et al. (44) 55/40 SIB 10 7.5 (8.7%)a‡ 8 in 6 months; 
54/44 PL 3.2 (3.8%)b‡ psychologist provided 
— — tailored advice 
Fujioka et al. (95) 89/60 SIB 20 4.4 (4.5%)a 8 in 6 months; 
86/60 PL 0.4 (0.5%)b — — individual dietary 
counseling 
James et al. (40) 352/204 SIB 10–20 — �11.0§ 10.2 (10%)b§ 12 in year 1; total 24 in 
115/57 PL � 7.0§ 4.7 (4.6%)a§	 2 years; monthly 
sessions with a 
dietitian with the 
option of returning 
every 2 weeks 
McMahon et al. (68) 150/79	 SIB 20 �4.4 4.4 (4.7%)a‡ 1 in 6 months; dietary 
— 74/41 PL �0.5 0.5 (0.7%)b‡	 advice 
Superscripts that differ (a and b) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid 
interpretation. 
* Treated by very-low-calorie diet for first month during which participants lost approximately 7.5 kg; data in the table reflect weight losses
 
from baseline, representing 13 months of treatment.
 
† Data reflect values from last-observation-carried-forward analysis.
 
‡ Sibutramine initiated after 2 weeks of a low-calorie diet and a 1.4 kg loss; data reflect weight losses from baseline.
 
§ Randomization and placebo initiated after 6 months of dieting plus sibutramine, during which patients lost about 11 kg; data in the table
 
reflect weight loss from baseline.
 
QD, once daily; SIB, sibutramine; PL, placebo.
 
Table 2. Randomized double-blind controlled trials of orlistat and lifestyle modification for obesity 
Randomized/ 6-Month 1-Year 2-Year 
completed Dose weight loss weight loss weight loss Number of 
Reference (n) (mg/TID) (kg) (kg) (kg) counseling visits 
Davidson et al. (70) 657/458 ORL 120 — 8.7 (8.8%)a 7.6 (7.6%) 18 in 1 year; total 24 in 2 
223/133 PL 5.8 (5.8%)b 4.0 (4.0%) years; dietary and exercise 
advice; 4 behavioral 
modification sessions/year 
Finer et al. (71) 114/73 ORL 120 �9.0a 8.8 (8.8%)a 10 in 6 months; total 16 in 1 
— 114/66 PL �6.6b 5.5 (5.5%)a	 year; dietary advice 
Hauptman et al. (49) 210/14 ORL 120 — 7.9 (7.9%)a* 5.1%* 5 in 1 year; total 9 in 2 years; 
212/122 PL 4.1 (4.2%)b* 1.7%* physician provided brief 
dietary and exercise advice; 
video-administered 
behavioral guidance 
Hollander et al. (69) 163/139 ORL 120 (�6.0%) (6.3%)a 9 in 6 months; total 18 in 1 
— 159/115 PL (�3.5%) (4.2%)b	 year; dietitian provided 
dietary and exercise advice; 
a minimum of 4 sessions 
included behavioral advice 
James et al. (96)† 23/9 ORL 120 8.6 (8.4%) (8.4%) 6 in 6 months; total 8 in 1 
— 23/11 PL 5.5 (5.7%) (2.6%)	 year; dietitian and obesity 
nurse provided dietary and 
exercise advice 
Karhunen et al. (86) 45/36 ORL 120 11.2a 13.1a �3 in 6 months; total 4 in 1 
45/36 PL 8.7b 8.6b — year; dietitian provided 
dietary counseling 
Rossner et al. (72) 244/181 ORL 120 (�8.5%) 9.8 (10.2%)a (7.8%) 8 in 6 months; total 16 in 2 
243/158 PL (�6.5%) 4.3 (4.5%)b (4.5%) years; dietitian provided 
dietary and behavioral advice 
Sjo¨stro¨m et al. (51) 343/284 ORL 120 10.3 (10.2%)* (�8%)* 16 in 1 year; total 24 in 2 
340/260 PL — 6.1 (6.1%)* (�4%)* years; dietitian provided 
dietary and behavioral advice 
Van Gaal et al. (97) 120/97 ORL 120 (9.8%)b 14 in 6 months; dietitian 
— — 123//96 PL (6.5%)a	 provided advice 
Zavoral (98) 1561/1107 ORL 120 — (9.2%)* — Inconsistent across sites; 
1119/722 PL (5.8%)* nonstandardized instruction 
in dietary, exercise, and 
behavioral advice 
Superscripts that differ (a and b) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid in 
interpretation. 
* Data reflect values from last-observation-carried-forward analysis.
 
†p values were not reported.
 
TID, three times daily; ORL, orlistat; PL, placebo.
 
Table 3. Short-term randomized controlled trials evaluating current or former anti-obesity medications and 
lifestyle modification 
Randomized/ Number of 
completed counseling Weight 
Reference Treatment groups (n) visits loss (kg) 
Brightwell and Naylor (66) 1) Lifestyle mod � placebo (PL) 1) 20/15 1) 3 1) 2.0 (2.0%)a 
(at 8 weeks) 2) Lifestyle mod � med (phentermine)* 2) 20/15 2) 3 2) 7.5 (8.3%)b 
Brownell and Stunkard (64) 1) Lifestyle mod alone 1) 43/39 1) 16 1) 7.1 (8.0%)a 
(at 16 weeks) 2) Lifestyle mod � med (fenflur)† 2) 69/62 2) 16 2) 10.8 (10.9%)b 
Craighead (63) 1) Med alone (fenflur)† 1) 16/13 1) 7 1) 4.8 (6.6%)a 
(at 16 weeks) 2) Lifestyle mod alone 2) 16/15 2) 16 2) 5.7 (7.7%)a 
3) Lifestyle mod � med (fenflur)† 3) 14/13 3) 16 3) 6.9 (8.8%)b 
Craighead et al. (62) 1) Med alone (fenflur)‡ 1) 10/9 1) 7 1) 6.0 (7.3%)a 
(at 26 weeks) 2) Lifestyle mod alone 2) 40/33 2) 26 2) 10.9 (12.0%)b 
3) Lifestyle mod � med (fenflur)‡ 3) 34/31 3) 26 3) 15.3 (15.6%)c 
Wadden et al. (73) 1) Med alone (SIB)§ 1) 19/13 1) 7 1) 5.6 (5.8%)a¶ 
(at 24 weeks) 2) Lifestyle mod � med (SIB)§ 2) 17/13 2) 20 2) 11.4 (11.0%)b¶ 
3) Lifestyle mod � LCD � med (SIB)§ 3) 17/17 3) 20 3) 17.9 (17.7%)c¶ 
Weintraub et al. (65) 1) Lifestyle mod � PL 1) 54/49 1) 14 1) 4.6 (4.9%)a 
(at 34 weeks) 2) Lifestyle mod � med (fen-phen)** 2) 58/54 2) 14 2) 14.3 (15.6%)b 
Weintraub et al. (99) 1) Lifestyle mod � PL 1) 18/10 1) 3 1) 4.4 (5.0%)a 
(at 24 weeks)	 2) Lifestyle mod � med (phentermine)†† 2) 20/14 2) 3 2) 10.0 (11.0%)b 
3) Lifestyle mod � med (fenflur)†† 3) 19/8 3) 3 3) 7.5 (8.4%)b 
4) Lifestyle mod � med (fen-phen)†† 4) 21/13 4) 3 4) 8.4 (10.1%)b 
Superscripts that differ (a, b, and c) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid in 
interpretation. 
* Medication dosage was 30 mg/d.
 
† Medication dosage was up to 160 mg/d.
 
‡ Medication dosage was up to 120 mg/d.
 
§ Medication dosage was up to 15 mg/d.
 
¶ Data reflect values from last-observation-carried-forward analysis.
 
** Medication dosage was 60 mg/d of phentermine and 15 mg/d of fenfluramine.
 
†† Medication dosages were: 30 mg/d of phentermine; 60 mg/d of feflurmaine; and 30 mg/d of fenfluramine plus 15 mg/d of phentermine. 
Lifestyle mod, lifestyle modification; med, medication; PL, placebo. 
results are generalizable to trials of lifestyle modification; 
however, the use of a placebo remains a potential 
confounder. 
In studies of 1- and 2-year durations, sibutramine (10 
to 20 mg/d) produced an average weight loss of 7 to 10 
kg, which was 5 kg greater than placebo plus lifestyle 
modification. Patients maintained 100% of their 6-month 
weight losses at 1 year (40,67,68), and 90% of their 1-year 
loss at 2 years (40) (Table 1). 
More studies have evaluated the long-term effects of 
orlistat. In 1-year studies, weight loss averaged 6 to 10 kg, 
equal to a 4-kg placebo-subtracted weight loss (49,51,69,72). 
In 2-year studies (49,51,70), weight losses averaged 5 to 8 
kg, which were also �4 kg greater than placebo. Across 
studies, patients maintained nearly 100% of their 6-month 
weight loss at 1 year and �75% of this loss at 2 years. The 
medication, compared with placebo, reduced the rate of 
weight regain but did not prevent it entirely. 
In summary, long-term studies of sibutramine and orlistat 
demonstrate that the medications significantly improve 
long-term weight loss compared with placebo when com­
bined with standard monthly or quarterly treatment visits. 
However, additional research, particularly with sibutramine, 
is needed to assess the long-term efficacy (�2 years) of 
these medications. It is also unclear whether medication 
would improve results on a more comprehensive behavioral 
weight-maintenance program (with biweekly patient visits) 
as described by Perri et al. (23). 
Does Adding Lifestyle Modification Improve 
the Results of Pharmacotherapy? 
Clearly, pharmacotherapy improves results of a modest 
program of lifestyle modification, but does adding lifestyle 
modification improve on the results of pharmacotherapy 
alone? This may seem like an inappropriate area of inquiry, 
given that pharmacotherapy is only recommended as an 
adjunct to a comprehensive lifestyle-modification program. 
In clinical practice, however, weight-loss medications are 
often used alone. 
Earlier studies of formerly approved weight-loss agents 
examined the effects of medication alone compared with a 
comprehensive program of lifestyle modification and the 
combination of the two therapies (62,63). Craighead et al. 
(62) found that individuals treated with fenfluramine in 
monthly, routine office visits lost an average of 6 kg in 26 
weeks; patients treated with weekly group lifestyle modifi­
cation alone lost 11 kg. However, patients treated with both 
medication and group lifestyle modification lost a signifi­
cantly greater amount—15 kg. Thus, the addition of life­
style modification improved the results obtained with treat­
ment by pharmacotherapy alone (and vice versa). A similar 
study (63) of only 16 weeks reached the same conclusions, 
although weight losses for all three groups were smaller 
than in the 26-week investigation. 
Only one study of currently approved medications exam­
ined whether adding lifestyle modification improved the 
results obtained by medication alone. In a 1-year trial, 
Wadden et al. (73) examined the effect of 15 mg/d of 
sibutramine combined with three interventions. Patients in 
the medication-alone group were instructed to consume a 
diet of 1200 to 1500 kcal/d and to walk �150 min/wk; 
they were not, however, provided any instruction in be­
havior change. Persons in the medication plus lifestyle-
modification group received the same diet and exercise 
prescription but attended weekly group treatment sessions 
for the first 5 months and monthly sessions for the remain­
der of the year. Patients in a third group received the same 
behavioral intervention but for the first 4 months were 
prescribed a 1000-kcal/d portion-controlled diet. After 6 
months, patients in the medication-alone group lost only 
5.8% of initial weight compared with significantly greater 
losses of 11.0% and 17.7% for participants in the second 
and third groups, respectively. Similar findings were found 
at 1-year follow-up. These findings illustrate that lifestyle 
modification improves the pharmacological treatment of 
obesity. This study, however, did not include a lifestyle-
modification-alone group, which precludes determination of 
whether pharmacotherapy improves on comprehensive life­
style modification treatment. 
Clearly, additional research on sibutramine and orlistat 
(as well as agents to be discovered) is needed to determine 
whether greater intensity of lifestyle modification improves 
the efficacy of these medications, as suggested by the study 
by Wadden et al. (73). The use in current placebo-controlled 
trials of low-intensity lifestyle programs may simulate prac­
tice in a primary-care setting and ensure that any adjunct 
behavioral treatment does not mask the effects of the drug. 
However, it is possible that the medication’s effects are 
enhanced by more aggressive lifestyle interventions. 
How Could Combining Medication and
 
Lifestyle Modification Result in Better
 
Weight Control than Either
 
Approach Used Alone?
 
As reviewed above, weight-loss medications seem to 
improve on the effects of low-intensity and possibly com­
prehensive lifestyle modification programs. An important 
question is how the combination of lifestyle modification 
and pharmacotherapy could be more effective than either 
approach alone. Three possible ways are discussed. 
Additive Hypothesis 
First, it is possible that the treatments act additively. Each 
treatment may target a unique set of variables, and com­
bined, target more variables and result in greater weight 
loss. Behavioral treatment teaches patients to control the 
external environment. Patients are instructed to control ex­
ternal prompts to eat by storing food out of sight, shopping 
from a list, avoiding fast-food restaurants, and keeping 
records of everything eaten. By contrast, medication would 
seem to modify principally biological variables that affect 
hunger, fullness, palatability, or fat absorption. 
Studies of formerly approved medications support these 
hypotheses. Investigations that compared fenfluramine and 
lifestyle modification found that patients who received be­
havior therapy showed significantly greater improvements 
in eating habits, cognitions, and adherence to their eating 
schedule (63,74). They also reported greater control of their 
weight and felt that the program was more helpful, com­
pared with patients treated by fenfluramine alone (63,74). 
By contrast, studies of the fenfluramine-phentermine com­
bination found that it was associated with greater improve­
ments in hunger (65) and evening fullness (65), and with 
reduced difficulty with dietary adherence (65), compared 
with behavioral treatment alone. The withdrawal of medi­
cation also resulted in increased hunger and decreased full­
ness (65). These studies suggest that medication and life­
style modification targeted different variables. 
A recent study of sibutramine reported similar findings 
(75). In an 18-week trial, sibutramine (15 mg/d) combined 
with intensive lifestyle modification (i.e., weekly group 
behavioral treatment) was compared with sibutramine plus 
minimal lifestyle intervention (i.e., monthly physician vis­
its) and with an intensive lifestyle-modification-alone 
group. At the end of treatment, patients treated with sib­
utramine plus minimal lifestyle modification reported sig­
nificant reductions in hunger and craving but no increases in 
their practice of weight-control behaviors (e.g., exercising, 
eating vegetables, following a meal plan). By contrast, those 
treated with intensive behavior modification alone reported 
little change in appetite but significant increases in their 
practice of weight-control behaviors. Participants who re­
ceived combined treatment (i.e., medication plus behavior 
therapy) seemed to reap the benefits of both approaches. 
They reported significant improvements in both appetite 
and their practice of weight-control behaviors. Based on 
these findings, behavioral and pharmacological treatments 
seem to target different variables; thus, an additive effect 
seems plausible. 
Synergistic Hypothesis 
A second possibility is that medication and behavioral 
treatment act synergistically and enhance one another’s 
efficacy. A synergistic effect would occur if the weight loss 
produced by combined treatment was greater than the sum 
of the weight losses produced from medication therapy and 
lifestyle modification alone. This hypothesis is suggested by 
examining the placebo-subtracted weight losses (an indica­
tion of medication efficacy) in studies of sibutramine. Spe­
cifically, in studies that prescribed 15 mg/d of sibutramine, 
the most intensive lifestyle-modification program, which 
included on-going dietary counseling sessions (43), resulted 
in a 9-kg placebo-subtracted weight loss, whereas the two 
studies that used less intensive lifestyle-modification ther­
apy (76,77) resulted in 7 and 6 kg placebo-subtracted weight 
losses, respectively. Thus, the greater intensity of lifestyle-
modification treatment may have improved the medica­
tion’s efficacy. This possibility, however, was only sug­
gested; it was not apparent for studies of sibutramine with 
10 mg or 20 mg or in studies of orlistat. 
There are a number of ways synergistic effects could 
occur. For example, behavioral treatment could enhance the 
effects of medication by improving medication adherence; 
self-monitoring, cue control, and similar behavioral tech­
niques could facilitate the behavior of taking medication. 
Conversely, by suppressing appetite, anorectic agents could 
facilitate adherence to lifestyle modification, including pa­
tients’ dietary and possibly exercise compliance. Improved 
appetite control could make it easier for patients to adhere to 
behavioral goals such as eating a low-calorie, low-fat diet 
and recording their food intake. It is also possible that 
medication could blunt the palatability and reduce food 
value (78), thereby making it easier for patients to adhere to 
an appropriate calorie level. 
Compensatory-Effects Hypothesis 
A third possibility is that combination treatment has 
compensatory effects. Each treatment may prevent the un­
toward effects produced by the other. For example, medi­
cation could counteract the declines in resting energy ex­
penditure (REE) and leptin that are associated with dieting 
and weight loss, and which ultimately slow weight loss. It 
might be possible to use medications such as leptin to 
reverse the decline in REE that occurs with energy restric­
tion and weight loss (79). 
Ultimately, additive, synergistic, and/or compensatory 
interactions may differ depending on the medication and 
lifestyle intervention used and the particular outcome vari­
able of interest (e.g., appetite vs. REE). In addition, new 
medications are likely to have new mechanisms of action. 
Clearly, multiple dimensions of therapeutic efficacy will 
need to be considered in evaluating how treatments interact 
to enhance weight loss. 
Options for Combining Medication and
 
Lifestyle Modification
 
Another important question is when and how best to 
combine medication and lifestyle modification to maximize 
weight loss and long-term weight control. A stepped care 
approach suggests that lifestyle modification should be pre­
scribed first, with pharmacotherapy provided only to those 
individuals who are unsuccessful, for example, in losing 
10% of initial body weight or in improving control over a 
risk factor (e.g., type 2 diabetes). Similarly, with a stepped 
approach, those who lost 10% would only be prescribed 
medication if they began to regain weight (for example, �2 
percentage points of their initial loss). Whereas this ap­
proach is logical from the standpoints of both safety and 
cost, some patients might benefit from receiving both life­
style modification and pharmacotherapy from the outset of 
treatment. This is particularly true of individuals who re­
ported a history of difficulty in losing weight by diet and 
exercise alone. Patients with a marked history of weight loss 
and regain (i.e., weight cycling) also might wish to begin 
taking medication as soon as they reached a weight-loss 
plateau (e.g., �1 month). Given the significant weight re­
gain that occurs with the withdrawal of either lifestyle 
modification or medication, the great majority of patients 
will require long-term treatment of some kind. At present, 
investigators know little about how best to prescribe life­
style modification and medication to maximize both short-
and long-term outcomes. There are at least four possible 
options, in addition to that of stepped care. 
Concurrent Administration 
One approach is to introduce both treatments from the 
outset and maintain both interventions long-term. Studies 
that evaluated this approach typically reduced the frequency 
of lifestyle counseling visits after the first 6 to 12 months, 
and therefore, did not provide definitive assessments of the 
possible benefits of this approach. Investigations with 
orlistat found that �60% to 75% of the weight lost during 
the first year of treatment was maintained at the end of the 
second year (while patients remained on medication), re­
sulting in a 5% to 8% weight loss at this time (49,51,70,72). 
The one long-term (i.e., 2-year) investigation of sibutramine 
that used this approach found that participants maintained 
�90% of their maximal weight loss (11%), which was 
achieved at 6 months (40). 
Similarly, data from formerly approved agents, including 
fenfluramine and dexfenfluramine, also revealed beneficial 
weight loss effects of simultaneously administering medi­
cation and lifestyle modification (80 –82). Whereas these 
data provide support for the concurrent administration of 
therapies, some have questioned whether this method is 
necessary, particularly when an aggressive dietary interven­
tion, such as a very-low-calorie diets (VLCD), is used (83). 
Medication is unlikely, for example, to augment weight loss 
when prescribed concurrently with a VLCD, but it does 
increase costs substantially. 
Lifestyle Modification Followed by Pharmacotherapy 
A second option is to boost the induction of weight loss 
by using the medication after lifestyle treatment has been 
initiated. Apfelbaum et al. (67) evaluated the effects of this 
approach by adding sibutramine after an initial month of 
treatment with a VLCD (providing 200 to 800 kcal/d), 
during which patients lost �7.5 kg. Patients who were 
subsequently assigned to sibutramine lost an additional 5.2 
kg during the ensuing year, whereas those who received a 
placebo gained 0.5 kg. These findings suggest that adding 
medication after a brief course of VLCD may facilitate 
larger weight losses. It is unclear, however, whether the 
medication would have induced additional weight loss if 
patients had lost 15 to 20 kg by adhering to a VLCD for 2 
to 3 months, as these diets are commonly prescribed. 
Studies of formerly approved medications also evaluated 
the short-term effects of adding pharmacotherapy after life­
style modification (63,66). In a study by Craighead (63), 
one group received fenfluramine during the second half 
(weeks 9 to 16) of a 16-week lifestyle-modification pro­
gram; in another group, medication was included only in the 
first half (i.e., weeks 1 to 8) of the program. At the end of 
the 16 weeks, those who received medication during the 
latter half of the program lost 9.3 kg, which was signifi­
cantly more than either the behavior therapy alone group 
(5.7 kg) or the group that received medication during the 
first but not second half of treatment (5.6 kg). Thus, adding 
medication during the second 8 weeks of treatment in­
creased weight losses by �3.5 kg. In contrast, an earlier 
24-week study of phentermine found that starting medica­
tion after 8 weeks of placebo and a program of modest 
lifestyle modification seemed to benefit only a subgroup of 
“slow losers” (66). Further studies are needed to determine 
if medication will reliably induce further weight loss in 
persons originally treated by lifestyle modification alone. 
Medication for Weight Maintenance 
Another option is to introduce pharmacotherapy later in 
treatment to facilitate the maintenance rather than induction 
of weight loss. With this approach, consistent with stepped 
care, medication could be introduced at a specific time-point 
when the rate of weight loss typically slows (e.g., 6 
months), after patients had met a weight-loss criterion (e.g., 
7% to 10% loss), or as a rescue strategy after patients had 
regained weight (e.g., 2% or more). 
Two studies of orlistat evaluated the effect of adding 
medication after a specific period of time. Hill et al. (84) 
randomly assigned obese subjects who had lost �8% of 
their initial body weight (by diet and exercise alone) to 
placebo or orlistat, which was administered for 1 year in 
combination with a weight-maintenance diet. At the end of 
the year, participants treated with medication regained less 
weight than did placebo-treated subjects (32.8% vs. 58.7% 
regain of lost weight, respectively). Similarly, Sjo¨stro¨m et  
al. (51) randomly assigned patients who lost 5 kg during the 
previous year to receive orlistat or placebo during a second 
year. During year 2, patients on orlistat lost an additional 0.9 
kg, compared with a mean regain of 2.5 kg in patients who 
continued on placebo. Overall, these and other (85) studies 
suggest that adding medication after treatment by diet and 
exercise may minimize weight regain while reducing 
the duration of exposure to medication and its potential 
side-effects. 
Two studies compared the approaches of prescribing 
medication to induce weight loss and continuing it for the 
long-term vs. using medication for weight maintenance 
only. One found that mean weight loss of patients who 
received orlistat continuously for 2 years did not differ 
significantly from that of patients who began the medication 
at year 1 (51). The other study also reported that participants 
who began orlistat after 1 year of treatment by lifestyle 
modification alone achieved the same weight loss at the end 
of 2 years as participants who had received medication for 
the entire 2 years (86). It is unclear why later medication 
administration resulted in similar weight losses as continu­
ous combined treatment. There seems to be a limit to the 
total amount of weight loss that is typically produced by 
current medications. Patients treated late by pharmacother­
apy seem to catch up with those treated early and in whom 
weight loss has plateaued. 
Intermittent Use of Medication 
A final approach is to administer medication and/or life­
style modification intermittently. Studies have shown inter­
mittent pharmacotherapy to be as (87,88) or almost as 
effective (89) as continuous medication. Munro et al. (90), 
for example, compared the effects of continuous and inter­
mittent treatment with phentermine. One group received 
alternating 4-week supplies of active and placebo pills; a 
second group received continuous placebo, and the third 
received continuous phentermine. After 36 weeks, the al­
ternating therapy with phentermine and placebo was as 
effective as continued daily treatment with phentermine, 
and both were superior to placebo. The authors concluded 
that there seemed to be no advantage in taking the medica­
tion continuously, because intermittent treatment was as 
effective, cheaper, and possibly safer. 
Similarly, intermittent therapy was found to be as effec­
tive as continuous therapy in a recent study of sibutramine. 
Wirth and Krause (88) randomized participants to sibutra­
mine administered continuously, sibutramine used intermit­
tently with placebo, or placebo given alone for 48 weeks. 
All groups received brief dietary counseling from their 
physician. After 1 year, there were no significant differ­
ences in weight losses between the intermittent vs. contin­
uous treatment groups (7.8 kg vs. 7.9 kg, respectively). 
In addition, the percentage of patients who experienced 
adverse events was similar in all groups. These findings 
again suggest that intermittent use of medication could save 
costs without sacrificing efficacy. 
Weintraub et al. (89) reported findings similar to those of 
Munro et al. (90) but came to a different conclusion. In this 
study, although the end-of-treatment weight losses were 
similar with intermittent and continuous therapies, continu­
ous medication (i.e., phentermine and fenfluramine) was 
judged preferable to intermittent therapy, primarily because 
of the adverse side effects that occurred when medication 
was reinitiated. Additional problems included weight gain, 
difficulty in adherence, and decreased appetite control dur­
ing periods without medication. 
In summary, adding medication to boost weight loss 
and/or promote weight maintenance may be a more effec­
tive and less costly option than prescribing both medication 
and lifestyle modification from the outset of treatment. 
Whereas it is possible that some patients (e.g., those with a 
history of unsuccessful weight-loss attempts or weight cy­
cling) would reap more benefit from being offered medica­
tion and lifestyle modification concurrently, the effects of 
such patient characteristics on treatment outcome need to be 
investigated. Further research is also needed to fully assess 
the relative benefits of treatments administered intermit­
tently or at specific time-points to maximize weight loss and 
maintenance. Findings may differ depending on the medi­
cation used and its specific side-effect profile. Studies are 
also needed to determine whether medications may be used 
to prevent weight gain during high-risk periods, including 
the winter holidays and times of acute stress. 
Potential Pitfalls of Combined Treatments 
Some practitioners have voiced concerns that medication 
may undermine lifestyle modification (91). For example, if 
medication reduces hunger, patients may not be motivated 
to practice strategies such as eating at regular intervals or 
eating high-fiber foods to prevent hunger and enhance sa­
tiety. Failure to practice these behaviors could undermine 
weight control in the long-term, particularly if medication 
was discontinued or its effects waned over time. 
The use of medication may also convey the message that 
obesity is “biological” in origin and that personal efforts to 
change this “disease” process are futile. Such sentiments 
could reduce weight-control self-efficacy and receptiveness 
to lifestyle modification, which teaches patients to see them­
selves as active participants in solving their problems. Sim­
ilarly, medication may foster external attributions for suc­
cess. When patients lose weight, they may attribute their 
success completely to the medication, and not to their own 
efforts, thus further undermining self-efficacy. Conversely, 
it is possible that the failure of medication to produce 
adequate weight loss could be ascribed to internal causes, 
such as inadequate personal self-control. The small but 
significant number of medication nonresponders may feel 
guilty or hopeless that the medication is not working and 
withdraw from weight-management efforts. 
Although there is no evidence that, when used together, 
medication and lifestyle modification limit one another’s 
effectiveness, researchers and practitioners should be sen­
sitive to the potential drawbacks of combined therapy. 
Investigators also should evaluate potential adverse behav­
ioral (e.g., completion of fewer food diaries) and psycho­
logical (e.g., decreased self-efficacy, motivation, self-es­
teem) effects of combining treatments. Practitioners should 
inform patients how the medication and the patient’s own 
efforts to modify diet and activity habits potentially com­
plement each other to produce a better outcome. 
Treatment and Research Implications 
Treatment Implications 
The data reviewed in this article clearly indicate that 
medications, when added to a low-intensity program of 
lifestyle modification, improve both the induction and 
maintenance of weight loss compared with lifestyle modi­
fication alone. Whereas it is likely that combining pharma­
cotherapy with more intensive lifestyle modification 
will improve results, data with currently approved agents 
are lacking. 
Research Implications 
There are a number of key unresolved issues that require 
future research. Foremost is the need for randomized control 
trials that include adequate control conditions. 
Figure 1: Research design for evaluating the effects of combined 
behavioral and pharmacological treatment. 
Research Design. The most rigorous test of combination 
treatment would require a 2 � 2 design in which minimal 
lifestyle modification was administered with placebo and 
medication, and intensive lifestyle modification was also 
provided with placebo and medication (see Figure 1). These 
four groups would provide several comparisons. 
First, it is important to measure independent treatment 
effects to evaluate the relative contribution of each therapy 
to combined treatment. Thus, the model includes groups 
that assess whether intensive lifestyle-modification treat­
ment is, in fact, more effective than a minimal lifestyle 
intervention program (i.e., comparison of cell #2 with cell 
#1) and whether medication is, in fact, superior to placebo 
(i.e., comparison of cell #3 with cell #1). The comparison of 
medication and placebo is relatively straightforward, al­
though consideration must be given to the dose of the 
medication to be used and whether it may be increased 
because of poor response either early or late in treatment. In 
addition, the use of placebos that produce side-effects would 
also be helpful, as double-blind procedures are often not 
maintained in medication trials because therapists and pa­
tients can discover a patient’s treatment conditions through 
observation of side effects (92). 
Selection of the lifestyle interventions presents more 
choices. As described previously, intensive lifestyle modi­
fication usually consists of 16 to 26 sessions of weekly 
group treatment that is provided by a dietitian, psychologist, 
or other health practitioner. This approach produces excel­
lent weight loss that may be increased further by the use of 
a meal replacement (100). Low-intensity lifestyle modifica­
tion, by contrast, could take a number of forms, ranging 
from 4 to 6 visits a year with a primary-care practitioner 
who provided brief diet and exercise counseling to weekly 
(or biweekly) visits of 5 to 10 minutes at which patients 
were weighed by a medical technician and praised for 
keeping food records. (Frequent weigh-ins alone could ac­
count for the success of intensive lifestyle modification.) 
Investigators may want to design minimal lifestyle interven­
tions that can be implemented in primary-care practice. 
Protocols used in most industry-sponsored trials have in­
cluded relatively few visits, consistent with primary-care 
practice. 
After the separate effects of medication and lifestyle 
intervention have been examined, one of the central ques­
tions concerning combined treatment may be addressed: 
does adding medication improve on the effects of intensive 
lifestyle modification alone? This question is answered by 
comparing weight losses and changes in health in the groups 
that receive intensive lifestyle modification combined with 
placebo (cell #2) vs. medication (cell #4). Results of previ­
ous studies lead us to predict that medication plus intensive 
lifestyle modification will induce significantly larger weight 
losses (and improvements in health) than placebo plus the 
same program of lifestyle modification. Perhaps the more 
important question is whether the first therapy will be more 
effective than the second in maintaining improvements in 
weight and health one or more years after weekly group 
treatment has been discontinued. 
Some have argued that it is inappropriate to test behav­
ioral interventions in combination with a placebo (61,91). 
Treatment is not administered this way in clinical practice, 
and the placebo could undermine the effectiveness of be­
havior therapy by not meeting patient’s expectations. The 
addition of a fifth treatment cell, intensive lifestyle modifi­
cation alone, corrects for this possible shortcoming. If no 
differences were consistently found between this treatment 
condition and intensive lifestyle modification with placebo, 
the fifth cell could be eliminated. 
The 2 � 2 design also addresses the question of whether 
intensive lifestyle modification improves on the results of 
pharmacotherapy. This is revealed by the comparison of 
treatment cell # 3 with cell #4. Intensive lifestyle modifi­
cation may be required to obtain the best results with most 
medications. As noted earlier, Wadden et al. (73) found that 
sibutramine plus minimal lifestyle instruction produced a 
weight loss less than one-half as large as that resulting from 
sibutramine combined with intensive group behavior mod­
ification. By contrast, some medications may be so potent 
that maximal weight loss may be achieved with only min­
imal lifestyle modification, as was suggested by a study of 
the fenfluramine-phentermine combination (93). 
The relative and combined effects of lifestyle modifica­
tion and pharmacotherapy will not be known until studies 
similar to those described above are conducted. We note 
that the cost of conducting trials that included four or five 
treatment conditions could be prohibitive. For studies in 
which the efficacy of medication, relative to placebo, has 
already been demonstrated, an alternative would be a three-
group design that compared 1) medication plus minimal 
lifestyle modification, 2) medication plus intensive lifestyle 
modification, and 3) intensive lifestyle modification alone. 
The design would address several issues concerning meth­
ods of maximizing the benefits of behavioral and pharma­
cological interventions. The results of these three-group 
designs could inform the design of second-generation stud­
ies. Future studies should fully describe the components of 
each treatment condition, including the intensity of lifestyle 
intervention, the training of individuals who delivered the 
therapy (e.g., psychologist, dietitian), and the frequency, 
duration, and content of treatment sessions. 
Mechanisms of Action. The means by which combined 
treatment potentially enhances monotherapy (i.e., pharma­
cotherapy or lifestyle modification alone) needs to be de­
termined. As a prelude to doing so, it will be important to 
better understand the specific variables that are associated 
with eating and inactivity, both in the short- and long-term. 
For example, it is unclear whether hunger and craving do, in 
fact, contribute to overeating and weight gain in most obese 
individuals. If found to be the case, investigators would 
want to evaluate whether treatments had an effect on these 
variables. The effects of medications, as well as behavioral 
interventions, on variables including food preoccupation, 
macronutrient selection, dietary restraint, hedonic ratings of 
food, food preferences, cognitions, and activity level need to 
be investigated. Possible effects of medication on optimism 
and expectations for success should also be evaluated. Once 
independent treatment effects are identified, the ways in 
which combined treatments work could be better deter­
mined. Obtaining information about treatment mechanisms 
is critical for the development of efficient and effective 
lifestyle-modification interventions. Depending on the med­
ication(s) used, the content of lifestyle-modification treat­
ments will likely need to be modified to maximize the 
effects of the medication. We have outlined a number 
of possibilities to explain the interaction of medication 
and lifestyle modification. These mechanisms should be 
tested empirically. 
Matching Patients to Treatment. Whether various sub­
types of obese patients do better with different interventions 
has not been studied adequately. Some patients may be 
resistant to weight loss with a particular medication and 
need more intensive lifestyle treatment or an alternative 
medication. The characteristics of treatment responders and 
nonresponders need to be clarified more fully. Perhaps 
patients in whom emotional complaints override somatic 
ones might find behavioral treatment most useful. Patients 
who complain of hunger or cravings might find pharma­
cotherapy most useful. Other variables such as gender, 
body-fat distribution, stress, degree of obesity, age, and 
medical conditions need to be evaluated in relation to var­
ious treatment outcomes. Research on patient-treatment 
matching is needed. 
Dissemination. Finally, investigators will need to identify 
methods by which combination treatment can be delivered 
in an economical and widespread fashion. There are a 
number of promising new methods for disseminating be­
havioral treatment, including internet-administered inter­
ventions (101). Perhaps both medical and behavioral pro­
fessionals need to be involved for combination treatment to 
be most effective. However, training medical practitioners 
and other medical staff to provide brief lifestyle counseling 
might be an equally or even more efficient means of pro­
viding combination care (93). 
Summary and Conclusions 
FDA-approved weight-loss medications improve the re­
sults of low-intensity programs of lifestyle modification for 
weight management. In addition, long-term use of medica­
tion facilitates the maintenance of weight loss. At present, 
however, investigators know little about how best to com­
bine lifestyle modification and medication to maximize 
short- and long-term improvements in weight and health. 
Research is needed to determine the types of lifestyle inter­
ventions that maximize the effects of orlistat and sibutra­
mine, as well as of medications to be discovered. Under­
standing the optimal means of combining behavioral and 
pharmacological therapies is critical to improving the man­
agement of obesity in both primary-care practice and in 
specialty clinics. 
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